katanin regulatory subunit B1 like 1 pseudogene 6Genealiases: []
Q-omics provides the consensus-scored KATNBL1P6 profile across patient tissues and cancer cell-line models. KATNBL1P6 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KATNBL1P6 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, KATNBL1P6 RNA expression shows 10,840 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where KATNBL1P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KATNBL1P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KATNBL1P6 survival associations across molecular data types. KATNBL1P6 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KATNBL1P6 RNA expression–survival associations across cancer types. High KATNBL1P6 expression shows unfavorable associations in UVM, BLCA, LIHC, KICH and ACC, but favorable associations in KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for KATNBL1P6 RNA expression.
This table summarizes KATNBL1P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KATNBL1P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KATNBL1P6 shows lower tumor expression in KIRC, KIRP and KICH and higher tumor expression in COAD. The KIRC box plot shows higher KATNBL1P6 RNA expression in normal versus tumor tissue (log2 FC = −0.055, t-test p < 0.001).
This table shows molecular features associated with KATNBL1P6 in patient tissues and cancer cell lines. In patient samples, KATNBL1P6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KATNBL1P6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE.
